French pharmaceutical giant Sanofi-Aventis on Feb. 16 won control of giant U.S. biotechnology group Genzyme after increasing its offer considerably in a drawn out battle.
Sanofi-Aventis will pay $20.1 billion for Genzyme, with a further payment of $3.8 billion depending on how the U.S. company performs, the two companies said in a statement.
The two boards unanimously approved the deal and hope to close at the beginning of the second quarter, they said.
Sanofi-Aventis initially offered $18.5 million or $69 per share in October last year after talks on a tie-up with Genzyme made no progress.
At $20.1 billion, or $74 per share, the deal is second only to Roche's acquisition of another US firm, Genentech for $46.8 billion in 2009.
Copyright Agence France-Presse, 2011
About the Author
Agence France-Presse
Copyright Agence France-Presse, 2002-2025. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.